AQR Capital Management LLC acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,642 shares of the biotechnology company’s stock, valued at approximately $1,695,000.
Other large investors also recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in bluebird bio during the first quarter valued at approximately $422,000. State Street Corp increased its stake in bluebird bio by 3.7% in the first quarter. State Street Corp now owns 1,611,032 shares of the biotechnology company’s stock valued at $146,443,000 after buying an additional 58,228 shares during the last quarter. Two Sigma Securities LLC bought a new stake in bluebird bio during the first quarter valued at approximately $304,000. Schwab Charles Investment Management Inc. increased its stake in bluebird bio by 9.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 169,839 shares of the biotechnology company’s stock valued at $15,439,000 after buying an additional 15,240 shares during the last quarter. Finally, BlackRock Inc. increased its stake in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after buying an additional 3,175,124 shares during the last quarter.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at 92.45 on Friday. The stock’s 50 day moving average is $96.49 and its 200-day moving average is $91.07. The stock’s market cap is $4.21 billion. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $123.75.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.59) EPS. On average, analysts predict that bluebird bio, Inc. will post ($6.78) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was reported by BNB Daily and is the property of of BNB Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/aqr-capital-management-llc-takes-position-in-bluebird-bio-inc-nasdaqblue-updated-updated.html.
BLUE has been the subject of a number of research reports. Evercore ISI initiated coverage on shares of bluebird bio in a research report on Wednesday. They set an “in-line” rating and a $102.00 target price for the company. Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 25th. BTIG Research downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and boosted their target price for the company from $37.05 to $108.25 in a research report on Friday, June 30th. Wedbush restated an “outperform” rating and set a $100.00 target price (down from $121.00) on shares of bluebird bio in a research report on Friday, June 23rd. Finally, Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Hold” and an average price target of $100.74.
In other news, Director Daniel Lynch sold 2,000 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $80.00, for a total value of $160,000.00. Following the completion of the transaction, the director now owns 3,400 shares in the company, valued at approximately $272,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Philip D. Gregory sold 1,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $99.04, for a total transaction of $148,560.00. Following the completion of the transaction, the insider now owns 37,279 shares of the company’s stock, valued at approximately $3,692,112.16. The disclosure for this sale can be found here. Insiders sold a total of 80,106 shares of company stock valued at $8,308,358 in the last quarter. Insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.